Caspase-9 zVAD-fmk p53-dependent cell death Mouse embryonic fibroblast Caspases are key effectors of programmed cell death. Down-and up-regulation of their activity are involved in different pathologies. In most cells, zVAD-fmk prevents apoptosis. However, unexpected effects of zVAD-fmk have been characterized in different laboratories, cell models and cell death processes. We have previously shown that zVAD-fmk accelerates p53-dependent apoptosis in rat embryonic fibroblasts. In this study, we pursued our investigations on zVAD-fmk effects and focused our study at the mitochondrial level in mouse embryonic fibroblasts (MEFs). In both primary and immortalized (by AgT or 3T9 protocol) MEFs, zVAD-fmk increased etoposide-induced loss of ΔΨm. This increase correlated with an increase of the number of apoptotic cells in primary and 3T9 MEFs, but did not in AgT MEFs. In both types of immortalized MEFs, zVAD-fmk regulated neither p53 levels nor transcriptional activities, suggesting that zVAD-fmk acts downstream of p53. In MEFs, zVAD-fmk increased p53-dependent loss of ΔΨm, cytochrome c release and caspase-9 activity. Indeed, zVAD-fmk inhibited effector caspases (caspases-3, -6, -7) as expected but increased caspase-9 cleavage and activity in etoposidetreated MEFs. Q-VD-OPh, another caspase inhibitor, also increased both loss of ΔΨm and caspase-9 cleavage in etoposide-treated MEFs. Invalidation of bax and bak suppressed p53-dependent cell death and zVAD-fmk regulation of this process. Invalidation of caspase-9 did not inhibit mitochondrial membrane depolarization but suppressed zVAD-fmk amplification of this process. Altogether, our data suggest that caspase-9 activity is upregulated by zVAD-fmk and is involved in an amplification loop of etoposide-induced cell death at the mitochondrial level in MEFs.
Introduction
Programmed cell death (PCD) is a physiological process required for embryogenesis, metamorphosis, tissue homeostasis and elimination of cells that are potentially detrimental to the organism. Misregulation of PCD has been implicated in many pathologies, such as cancers, neurodegenerative and autoimmune diseases [1, 2] . Different types of PCD have been described including apoptosis, necrosis and autophagy, which diverge on criteria such as the initiating death signals, morphological alterations, mitochondrial events, protease and/or nuclease activations, as well as functional and immunological aspects [3, 4] . We focused our study on mitochondrial-dependent cell death induced by the tumor suppressor p53. In response to stresses such as DNA damages, oncogene activation or hypoxia, the transcription factor p53 induces the intrinsic pathway of apoptosis [5, 6] by trans-activating genes encoding proteins involved in the induction of apoptosis, such as proapoptotic Bcl-2 family members (Bax, Puma or noxa) [7, 8] . These proteins as well as p53 itself [9] can induce mitochondrial modifications, such as mitochondrial internal membrane depolarization and outer membrane permeabilization. These modifications induce the release of apoptogenic proteins, including cytochrome c and Smac/ DIABLO, from the mitochondrial inter-membrane space to the cytosol. Cytochrome c release results in the formation of the apoptosome, a large complex composed of cytochrome c, ATP/dATP, Apaf-1 and procaspase-9. The formation of this apoptosome requires the interaction of Apaf-1 and procaspase-9 via their respective CARD domain, and activates the initiator caspase-9, which in turn activates effector caspases (caspase-3, -6 and -7) [10, 11] . Smac/DIABLO cooperates to the regulation of the apoptotic process by neutralizing the caspase-3, -7, -9 inhibitor XIAP in the cytosol [12, 13] . In some cell types, p53 also regulates the extrinsic apoptotic pathway by controlling the expression of genes coding for death receptor family members. This pathway is activated by death receptors able to cross-activate the intrinsic pathway via the caspase-8-dependent cleavage of Bid, a proapoptotic Bcl-2 family member [14] .
A molecular hallmark of apoptosis is the activation of caspases, cysteinyl proteases that execute cell death through the cleavage of a broad Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / b b a m c r spectrum of cellular protein targets after an Asp residue [11, [15] [16] [17] . Apoptotic caspases can be classified as initiator (caspase-2, -8, -9, -10) or effector caspases (caspase-3, -6, -7). The classical apoptotic pathways require a sequential activation of initiator caspases (requiring adapter proteins) and effector caspases (cleaved by activated initiator or effector caspases). Most of the studies on both the function and the regulation of caspases have been performed using pharmacological inhibitors [18] . Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk) is the most used cell permeable broad-caspase inhibitor. In most of the cells, zVAD-fmk prevents the apoptotic process. However, we have previously shown that zVAD-fmk increases p53-dependent cell death in rat embryonic fibroblasts [19] [20] [21] . In REtsAFs, a rat embryonic fibroblast cell line immortalized with a temperature-sensitive mutant (tsA58) of the simian virus 40 large tumor antigen (AgT), we have shown that p53-dependent cell death in the presence of zVAD-fmk diverges from the classical pathway. This cell death process induced in the presence of zVAD-fmk could not be inhibited by Bcl-2 overexpression, in contrast to the classical pathway [19, 21] . Furthermore, we have shown that zVADfmk could modify p53-transcriptional activities in these cells. Indeed, p53-dependent trans-activation was decreased while p53-dependent trans-repression was increased in the presence of zVAD-fmk as shown by the study of p53 target gene expression and microarray analysis [20] . Different laboratories presented evidences that zVAD-fmk can induce switches between apoptotic, necrotic and autophagic cell deaths [22, 23] and that zVAD-fmk cannot prevent all types of caspase-dependent apoptosis [19] [20] [21] 24, 25] . These unexpected effects of zVAD-fmk were detected on different cell death pathways, in different cell types and after different cell death stimuli. Altogether, these results suggest that the inability of zVAD-fmk to prevent some apoptotic cell deaths or to induce a switch in the cell death process might be due to the fact that this inhibitor does not inhibit all caspases to the same extent. To test this hypothesis and to progress in the comprehension of zVAD-fmk effect on p53-dependent cell death, we pursued our investigations on the zVADfmk effect in mouse embryonic fibroblasts (MEFs), in primary cultures and in immortalized cell lines issued from wild type, Bax −/− Bak −/− and caspase-9 −/− mice. In the present study, we show that: (i) zVADfmk accelerates mitochondrial membrane depolarization and cytochrome c release occurring during etoposide-induced cell death; (ii) although zVAD-fmk classically inhibited effector caspases, it did not inhibit the initiator caspase-9 but in contrast it induced the accumulation of the active form of this caspase; and (iii) caspase-9 induces a mitochondrial amplification loop during etoposide-induced cell death in MEFs. 
Materials and methods

Cell culture and drugs
RT-PCR assay
At 70% confluence, 3T9 MEFs were incubated with or without etoposide +/−zVAD-fmk. After 16 h of treatment, total RNA was isolated using the guanidium isothiocyanate method. RT-PCR was performed to examine the levels of p53, mdm2, p21 and noxa mRNAs as previously described [26] . RT-PCR of 18S rRNA was used as a control.
Cytosol fraction preparation
At 70% confluence, 3T9 MEFs were incubated with etoposide +/− zVAD-fmk for different treatment times (0, 4, 8, 12, 16 and 19 h). Attached and floating cells were collected and centrifuged 5 min at 200 g. Pellets were resuspended in 200 μL of Lysis buffer (10 mM Hepes-KOH pH 7.4, 0.1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM protease inhibitor cocktail AEBSF (Roche)). After 30 min incubation at 4°C, cell disruption was completed by passing the cells through a 0.4 × 20 mm needle 10 times. 1/3 of the extract was conserved as the total extract, 2/3 of the extract was centrifuged for 5 min at 4°C at 52 g to eliminate nuclei. The supernatant was further centrifuged 30 min at 4°C at 7000 g to eliminate mitochondria and reticulum. The supernatant corresponded to the cytosol fraction and was analyzed by Western blot.
Western blot analysis
At 70% confluence, MEFs were incubated with or without etoposide, zVAD-fmk and/or Q-VD-OPh. After different treatment times, cells were harvested, lysed and frozen at −20°C. Proteins (10-30 μg), from total cell extracts or from cytosolic extracts, were separated in NuPAGE 4-12% Bis-Tris polyacrylamide gels according to the manufacturer's instructions (Invitrogen) and transferred onto a PVDF membrane (Millipore). The primary antibodies used were anti-p53 (Pab 122, gift from E. May, IRSC, Villejuif, France), anti-phospho-p53 (Ser-15, Cell Signaling), anti-actin (Sigma), anti-cytochrome c (BD Pharmigen), anti-VDAC (gift from C. Brenner, UVSQ, Versailles, France), anti-lamin A/C (Cell Signaling), anti-enolase (gift from N. Lamande, College de France, Paris), anti-caspase-9 (5B4, Abcam), anti-cleaved caspase-3 (Asp175, Cell Signaling), anti-cleaved caspase-6 (Asp162, Cell Signaling), and anti-tubulin (MAS078, Sera-Lab). Secondary antibodies (peroxidase-conjugated) were anti-rabbit, anti-mouse or anti-rat immunoglobulin (Biosystem). Immunoreactive bands were detected by chemiluminescence using the Immobilon kit (Millipore).
Immunocytochemistry
3T9 MEFs were plated onto glass coverslips in complete medium. At 60% confluence, cells were incubated with or without etoposide and/or zVAD-fmk. Immunocytochemistry analysis was performed as previously described [26] . In the present study, we used a mouse monoclonal anti-cytochrome c (BD Bioscience) as primary antibody and a FITC-conjugated anti-mouse antibody (Jackson ImmunoResearch Laboratory) as secondary antibody. Nuclei were stained with Hoechst 33342. Immunolabeled cells were examined by epifluorescence under a DMR Leica microscope equipped with an Olympus DP70 photo camera using the DP Manager software.
Caspase-3/7 and caspase-9 activity assays
The Apo-ONE™ Homogeneous Caspase-3/7 Assay and the CaspaseGlo™ 9 Assay (Promega) were used to detect caspase-3/-7 and caspase-9 activities in 3T9 MEFs treated with etoposide +/− zVADfmk according to the manufacturer's instructions.
Cell transfection
Caspase-9 KO AgT MEFs were plated in 12-well plates for flow cytometry analysis, and in 60 mm diameter plates for Western-blot analysis at a density of 10 5 cells/ml. At 80% confluence, cells were transfected with 125 ng (for 12-well plate) or 1 μg (for 60 mm plate) pCDNA 3 -caspase-9 expression vector in the presence of Lipofectamine™ Transfection Reagent and PLUS™ Reagent in DMEM (Invitrogen) and incubated for 5 h at 37°C according to the manufacturer's instructions. Human caspase-9 expression vector was a generous gift from Patrick Melhen (Apoptosis, Cancer and Development Laboratory, Centre Léon Bérard, Lyon, France). After 24 h of culture in complete medium, transfected cells were incubated with etoposide for 16 h. Then, the mitochondrial membrane potential was analyzed by flow cytometry after Mito Tracker Red CMXRos staining and cell lysates were analyzed by Western-blot as previously described.
Statistical analysis
Each bar of the different graphs indicates the average measure and standard error of at least three independent experiments, and Pvalues are from paired two-tailed Student's t-tests.
Results
zVAD-fmk increases etoposide-induced mitochondrial membrane depolarization in MEFs
In order to test the effect of zVAD-fmk on p53-dependent apoptosis in mouse embryonic fibroblasts (MEFs) that are either spontaneously immortalized (3T9 MEFs [27] ), immortalized by transfection of SV40 AgT (AgT MEFs) or not immortalized (primary MEFs), we used etoposide, a DNA damage-inducing drug, to activate p53. The cell death process induced by etoposide in the presence or absence of zVAD-fmk was analyzed by flow cytometry after DiOC 6 (3) and propidium iodide (PI) staining (Fig. 1) . Apoptotic cells corresponded to the cells with three characteristics: low PI staining to exclude primary and secondary necrotic cells, low DiOC 6 (3) staining indicating a low mitochondrial membrane potential ΔΨm, and low cell size (i.e. condensating cells). In AgT MEFs, etoposide increased the percentage of apoptotic cells and the addition of zVAD-fmk classically decreased this effect (Fig. 1A) . In 3T9 MEFs and in primary MEFs, zVAD-fmk surprisingly increased the percentage of apoptotic cells (Fig. 1B, C) . The effect of zVAD-fmk was more pronounced (earlier and higher) in primary MEFs than in the established cell line 3T9 MEFs, suggesting a physiological relevance of this process. Then, we analyzed the percentage of cells with low ΔΨm (whatever the cell size) in the three types of MEFs. zVAD-fmk increased the percentage of cells with low ΔΨm in primary and immortalized MEFs. Thus, these results suggest that: (i) zVAD-fmk differently affected late events of apoptosis, in particular cell condensation, depending on the immortalized state, and (ii) zVAD-fmk accelerates the decrease of mitochondrial membrane potential in the three types of MEFs by acting either upstream or at the level of mitochondrial events.
zVAD-fmk has been reported to switch between different cell death modes (apoptosis, necrosis, autophagy, …) [22, 23, 28] . In etoposide-treated MEFs, zVAD-fmk did not significantly increase necrosis, autophagy and LEI/L-DNAse II caspase-independent cell death (data not shown). Only apoptosis was detected to be regulated by zVAD-fmk in this cellular model.
zVAD-fmk does not modify p53 transcriptional activity after etoposide treatment in 3T9 MEFs
We have previously shown that zVAD-fmk modifies both p53 stability and p53-transcriptional activities in rat embryonic fibroblasts [20, 21] . Therefore, we examined the status of p53 (mRNA and protein levels) and some of its targets (at the mRNA level) in the presence or absence of etoposide and/or zVAD-fmk in mouse embryonic fibroblasts. In 3T9 MEFs, addition of etoposide and/or zVAD-fmk did not modify the levels of p53 mRNAs and protein (Fig. 2) . In contrast, addition of etoposide induced an increase of the level in serine 15-phosphorylated p53 (Fig. 2B ) as well as in mdm2, p21 and noxa mRNA levels ( Fig. 2A) , showing that etoposide induces p53-transcriptional activity. The addition of zVAD-fmk modified neither the p53 levels nor the mRNA levels of p53 targets in the presence of etoposide, suggesting that zVAD-fmk does not regulate p53-transcriptional activity in 3T9 MEFs. Altogether, these results suggest that zVAD-fmk increases mitochondrial membrane depolarization downstream of p53 transcriptional activity in mouse embryonic fibroblasts after etoposide treatment.
Bax and/or Bak are involved in etoposide-induced cell death in the presence or absence of zVAD-fmk
We then examined the possible involvement of Bax/Bak or reactive oxygen species (ROS) accumulation in the cell death process occurring in 3T9 MEFs after etoposide treatment in the absence or in the presence of zVAD-fmk.
To determine whether Bax and Bak are required for etoposideinduced cell death and for the regulation of this process by zVAD-fmk, we used DKO 3T9 MEFs (Bax
Mitochondrial membrane depolarization, as assessed by flow cytometric ΔΨm analysis, induced by etoposide in the presence or absence of zVAD-fmk in 3T9 MEFs (after 16 h of treatment) was not detected in DKO 3T9 MEFs even after longer treatments (16 and 45 h of treatment) (Fig. 3A) . Our results show that Bax and/or Bak are required for etoposide-induced loss of ΔΨm and for zVAD-fmk-induced increase of this depolarization in mouse embryonic fibroblasts. ROS accumulation could be involved in mitochondrial-membrane potential collapse and cell death. Thus, we examined ROS production induced by etoposide in 3T9 MEF cells in the absence or presence of zVAD-fmk by flow cytometry after DCFH-DA staining. Whatever the treatment (etoposide+/− zVAD-fmk), DCF positive 3T9 MEFs could not be detected by flow cytometry in contrast to DCF positive etoposide-treated HeLa cells, which were used as positive control (Fig. 3B) . This result suggests that etoposide in the presence or absence of zVAD-fmk does not activate ROS production in mouse embryonic fibroblasts.
zVAD-fmk increases cytochrome c release after etoposide-treatment
We then examined the release of cytochrome c from mitochondria to the cytosol after etoposide-treatment in the presence or absence of zVAD-fmk in 3T9 MEFs. Immunocytochemistry experiments show that cytochrome c was principally detected in the mitochondria in the absence of cell death inducer (Fig. 4A, B) . After etoposide treatment, cytochrome c release to the cytosol was detected in about 10% of the cells. The addition of zVAD-fmk increased the percentage of cells with cytochrome c release in the presence of etoposide up to 34%. zVAD-fmk alone had no effect on cytochrome c localization. After etoposide treatment in the presence or absence of zVAD-fmk, dying cells detached from the Petri dish. Thus, we analyzed the level of cytosolic cytochrome c in all cells (both attached and floating cells) after cytosolic extraction and Western-blot analysis (Fig. 4C) . The detection of cytosolic enolase and the absence of detection of both mitochondrial VDAC and nuclear lamin A/C in the cytosolic fractions confirmed the efficiency of the enrichment. All these proteins could be detected in total cell extracts (control lanes). The amount of cytochrome c detected in the cytosolic fractions after etoposide treatment strongly increased in the presence of zVAD-fmk. Thus, we have shown that zVAD-fmk increases cytochrome c release after etoposide treatments in mouse embryonic fibroblasts by two experimental processes. 
zVAD-fmk upregulates initiator caspase-9 but downregulates effector caspases after etoposide treatment
In most of the cells, cytochrome c release induced the formation of the apoptosome and the activation of initiator caspase-9 and effector caspases (-3, -6 and -7). We studied the cleavage and activity status of these caspases in 3T9 MEFs treated with etoposide and/or zVAD-fmk. After etoposide treatment, cleaved forms of caspase-9, caspase-3 and caspase-6 were detected in 3T9 MEFs by Western-blot (Fig. 5A) . Surprisingly, the addition of zVAD-fmk in the presence of etoposide increased the level of cleaved caspase-9, while zVAD-fmk modified caspase-3 cleavage and inhibited caspase-6 cleavage. An upper cleaved form of caspase-3 was detected in the presence of zVADfmk, which probably corresponded to an incompletely cleaved form of this caspase.
To determine whether the cleaved forms of caspase-9 and caspases-3 detected in the presence of etoposide and zVAD-fmk were functional, we measured caspase-9 and caspase-3/-7 activities. In 3T9 MEFs, the etoposide treatment increased both caspase-9 ( Fig. 5B ) and caspase-3/-7 (Fig. 5C ) activities. Adding zVAD-fmk down-regulated caspase-3/-7 activity but, in contrast, up-regulated caspase-9 activity in mouse embryonic fibroblasts.
In most cells, caspase-6 is cleaved by active caspase-3. The absence of caspase-6 cleavage in the presence of etoposide and zVAD-fmk in 3T9 MEFs (Fig. 5A) suggested that caspase-6 is cleaved by caspase-3 in etoposide-treated MEF cells and that zVAD-fmk inhibited caspase-6 by inhibiting caspase-3. Etoposide treatment in the absence of zVAD-fmk induced lamin A/C cleavage (a caspase-6 substrate) in 3T9 MEFs suggesting caspase-6 activation in this condition. Addition of zVAD-fmk inhibited both etoposide-induced caspase-6 activity and lamin A/C cleavage in 3T9 MEFs cells.
Altogether, our data showed that during etoposide-induced apoptosis, zVAD-fmk classically inhibited effector caspases in mouse embryonic fibroblasts but surprisingly, increased caspase-9 activity.
Q-VD-OPh increased etoposide-induced loss of ΔΨm and caspase-9 cleavage in 3T9 MEFS
We tested another broad-spectrum caspase inhibitor, Q-VD-OPh in 3T9 MEFs. As zVAD-fmk, Q-VD-OPh increased etoposide-induced loss of mitochondrial membrane potential as assessed by flow cytometry analysis of ΔΨm (Figs. 1B, 3A, 6A ). We also showed by Western-blot (Fig. 6B ) that Q-VD-OPh increased the level of etoposide-induced cleaved caspase-9 and modified caspase-3 cleavage, to the same extent as zVAD-fmk. Thus, using two different caspase inhibitors, zVAD-fmk and Q-VD-OPh, we demonstrated a correlation between the loss of ΔΨm and caspase-9 cleavage in 3T9 MEFs.
Caspase-9 activates an amplification loop at the mitochondrial level
Our study suggests that caspase-9 is a key caspase in the mitochondrial membrane depolarization induced by etoposide in the presence of zVAD-fmk in 3T9 MEFs. In an attempt to progress in the characterization of its function, we analyzed the process induced by etoposide in the presence or in the absence of zVAD-fmk in a mouse embryonic fibroblast cell line issued from caspase-9 knock-out mice (caspase-9 −/− AgT MEFs).
First, we controlled that etoposide induces p53 transcriptional activity in caspase-9 −/− AgT MEFs to the same extent as in control AgT
MEFs issued from wild type mice (Fig. 7A) . Analysis by RT-PCR showed that etoposide in the presence or absence of zVAD-fmk induced a similar increase of noxa, mdm2 and p21 mRNA levels in both cell lines. Then, we examined the status of caspase-9 and caspase-3 in these cell lines (Fig. 7B) . In caspase-9 −/− AgT MEFs, no proform or cleaved caspase-9 was detected whatever the treatment in contrast to control AgT MEFs. In these control cells, zVAD-fmk increased the level of cleaved caspase-9 after etoposide treatment as previously shown in 3T9 MEFs. In caspase-9 −/− AgT MEFs, we did not detect cleaved caspase-3 whatever the treatment, showing that caspase-9 is required for caspase-3 activation in MEFs cells after etoposide treatment. We further analyzed mitochondrial membrane depolarization by cytometry after DiOC 6 (3) and PI staining (Fig. 7C) . Etoposide treatment increased the percentage of cells loosing ΔΨm at a similar level in both cell lines. The addition of zVAD-fmk in the presence of etoposide increased this effect in AgT MEFs. In caspase-9 −/− AgT MEFs, the percentage of cells with a loss of ΔΨm after etoposide treatment was not modified by the presence of zVAD-fmk. Thus, although caspase-9 is not required for etoposide-dependent mitochondrial membrane depolarization, caspase-9 activity is required for the amplification of this process by zVAD-fmk.
To confirm that caspase-9 can induce an increase of mitochondrial membrane depolarization, we expressed caspase-9 in caspase-9 −/− AgT MEFs by transfection and analyzed the loss of ΔΨm in the absence or in the presence of etoposide in transfected cells (Fig. 7D,  E) . In the absence of etoposide, overexpression of caspase-9 (both proform and cleaved forms could be detected) induced loss of ΔΨm to the same extent as etoposide-treated control cells. In the presence of etoposide, cleaved caspase-9 level increased as well as loss of ΔΨm induced in caspase-9 transfected cells. Thus, overexpression of caspase-9 in caspase-9 −/− AgT MEFs increased mitochondrial membrane depolarization induced by etoposide. Altogether, our data show that caspase-9, which was up-regulated by zVAD-fmk or by transfection, induces an amplification loop at the mitochondrial level of the cell death process induced by etoposide in MEFs.
Discussion
In the present study, we examined the effect of zVAD-fmk in etoposide-induced cell death in mouse embryonic fibroblasts and showed that zVAD-fmk can regulate this cell death process at the mitochondrial level. Indeed, zVAD-fmk increased etoposide-induced mitochondrial membrane depolarization in MEFs, whether the cells were immortalized (3T9 and AgT MEFs) or not (Figs. 1 and 7) . The effect of zVAD-fmk on ΔΨm was correlated with an increase in the number of apoptotic cells in primary and 3T9 MEFs. This correlation was not detected in AgT MEFs. However, longer etoposide treatment in the presence of zVAD-fmk induced late events of apoptosis, like cell size reduction and DNA fragmentation (data not shown). Our results suggest that immortalization of MEFs by the AgT could modify the level and/or the activity of factors involved in late events of the apoptotic process (nuclear and/or cell condensation) compared to primary MEFs. These modifications remain to be characterized. In both immortalized MEFs (AgT and 3T9 MEFs), zVAD-fmk modified neither p53 mRNA and protein levels nor p53 transcriptional activities (in particular the trans-activation of noxa, mdm2 and p21) induced in the presence of etoposide (Figs. 2 and 7) . The regulations of p53-transcriptionnal activities induced by zVAD-fmk characterized in rat embryonic fibroblasts [20] were not detected in MEFs. These differences between both cellular models could reflect either differences in cellular contents between rat and mouse, or differences in the p53 induction mode (etoposide treatment in MEFs versus temperature increase in REtsAF cell lines). Our unpublished data are in favor of the first hypothesis. In etoposide-treated REtsAF cells, zVAD-fmk increased p53 stability and phosphorylation (Ser-15) as well as puma trans-activation (data not shown). These data suggest that the effect of zVAD-fmk on etoposide-induced cell death is located downstream of p53 regulation in MEFs. We thus focused our study on mitochondrial events and showed that zVAD-fmk accelerates the loss of ΔΨm, cytochrome c release in the cytosol and caspase-9 activation in etoposide-treated 3T9 MEFs (Figs. 1, 4, 5) . We also showed that Bax and Bak are required for etoposide-induced loss of ΔΨm in the absence or presence of zVAD-fmk, in contrast to ROS production that was not detected in MEF cells (Fig. 3) . These data let us hypothesize that zVAD-fmk could induce an amplification loop of an etoposideinduced cell death at the mitochondrial level in MEFs.
Two presumed broad caspase inhibitors, zVAD-fmk and Q-VD-Oph, increased etoposide-induced loss of ΔΨm in 3T9 MEFs (Figs. 1 and 6 ), suggesting that both drugs act via the regulation of caspase activities. The study of caspase activities by analysis of their cleavage, activity and/ or the cleavage of specific targets after etoposide treatment in MEFs (Figs. 5, 6, 7) showed that: (i) zVAD-fmk classically inhibited effector caspases (i.e. caspase-3, -6 and -7), (ii) zVAD-fmk did not inhibit the initiator caspase-9 and in contrast induced an increase of the active forms of this caspase, and (iii) Q-VD-OPh induced an accumulation of autocleaved caspase-9. One hypothesis to explain these data is that the catalytic site of the proform and the auto-cleaved form of caspase-9 could not be accessible to zVAD-fmk, and to Q-VD-OPh, due to their integration into the apoptosome and/or post-translational modifications (such as phosphorylation). Indeed, the activation of caspase-9 and its regulations are quite complex [11, 16, [30] [31] [32] [33] [34] . Caspase-9 is activated through autocatalytic intra-chain cleavages into the apoptosome, and at least two cleavages are involved in the generation of mature caspase-9. The pro-, auto-cleaved and mature forms present caspase activity. However, conformational and catalytic specificities of these forms differ. Two previous reports have shown that zVAD-fmk does not inhibit the autocleavage of procaspase-9 while it inhibits procaspase-3 cleavage by mature caspase-9 [32, 35] , suggesting that zVAD-fmk inhibits only mature forms of caspase-9. In the presence of etoposide, zVAD-fmk inhibited neither the auto-cleavage of procaspase-9 nor the processing of procaspase-3 by caspase-9, suggesting that zVAD-fmk does not inhibit any of the different forms of caspase-9 in MEFs. zVAD-fmk inhibited the last processing step of caspase-3 cleavage, which requires caspase-3 activity and not caspase-9 activity. The increase in both autocleaved caspase-9 level and caspase-9 activity could be the result of an increase in the auto-cleavage process and/or the result of an inhibition of the degradation of cleaved caspase-9. zVAD-fmk increases mitochondrial membrane depolarization and cytochrome c release suggesting that it can result in an increase at the cell level in apoptosome activity and thus in an increase of auto-cleaved caspase-9 levels in the presence of zVAD-fmk. However, we cannot exclude the hypothesis that zVAD-fmk could also regulate the proteasome activity and that accumulation of auto-cleaved caspase-9 could result in part from this regulation. Interactions between cell death and proteasomal degradation were previously characterized [35, 36] . caspase-9 increased etoposide-induced mitochondrial membrane depolarization. The correlation between cleaved caspase-9 level and loss of ΔΨm suggests that caspase-9 induces mitochondrial membrane depolarization and an amplification loop of the cell death process induced by etoposide. Thus, although caspase-9 is not required for etoposide-induced loss of ΔΨm in MEFs cells, caspase-9 is required for the amplification of this process by zVADfmk. Such a positive feedback loop at the mitochondrial level could involve a cleavage of an anti-apoptotic member of the Bcl-2 family as described in other systems [37, 38] .
In conclusion, we demonstrate here for the first time that caspase-9, which is up-regulated by zVAD-fmk, induces an amplification loop at the mitochondrial level of the cell death process induced by etoposide in mouse embryonic fibroblasts. Noxa, mdm2, p21 mRNA and 18S rRNA levels were analyzed by RT-PCR (A). Caspase-9 (proform and cleaved form), cleaved caspase-3 and actin levels were analyzed by Westernblot (B). Cells with mitochondrial membrane depolarization were analyzed by flow cytometry after DiOC 6 (3)/PI staining (C). Student's t tests were performed (*p b 0.001, ns: no significant difference, n = 7). (D, E) Caspase-9 −/− AgT MEFs were transfected by a human caspase-9 expression vector and incubated with etoposide for 16 h. Cells with mitochondrial membrane depolarization were analyzed by flow cytometry after CMX-ros staining (D). Caspase-9 (proform and cleaved form) and actin levels were analyzed by Western-blot (E). Student's t tests were performed (*p b 0.001, ns: no significant difference, n = 3).
